

# WOAH Reference Laboratory Reports Activities 2024

This report has been submitted: 23 janvier 2025 14:35

## LABORATORY INFORMATION

<b>*Name of disease (or topic) for which you are a designated WOAH Reference Laboratory:</b>	Glanders
<b>*Address of laboratory:</b>	
<b>*Tel:</b>	+49-3641 804 2100
<b>*E-mail address:</b>	heinrich.neubauer@fli.de
<b>Website:</b>	<a href="https://www.fli.de/de/startseite/">https://www.fli.de/de/startseite/</a>
<b>*Name (including Title) of Head of Laboratory (Responsible Official):</b>	Prof. Neubauer, Heinrich
<b>*Name (including Title and Position) of WOAH Reference Expert:</b>	Prof. Neubauer, Heinrich
<b>*Which of the following defines your laboratory? Check all that apply:</b>	Governmental

## TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOAH Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
CFT, IB, ELISA	Yes	1	192
Direct diagnostic tests		Nationally	Internationally

## TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOAH?

## Heinrich Neubauer - - GERMANY

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOA Members?

Yes

Type of reagent available	Related diagnostic test	Produced/ provide	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	No. of recipient WOA Member Countries	Country of recipients
control DNA	PCR	FLI	0	1µg	1	TUNISIA,
control DNA	PCR	FLI	0	1µg	1	EGYPT,

4. Did your laboratory produce vaccines?

Not applicable

5. Did your laboratory supply vaccines to WOA Members?

Not applicable

## TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

7. Did your laboratory validate diagnostic methods according to WOA Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

No

9. Did your laboratory validate vaccines according to WOA Standards for the designated pathogen or disease?

No

## TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOA Members?

Yes

Name of WOA Member Country seeking assistance	Date	Which diagnostic test used	No. samples received for provision of diagnostic support	No. samples received for provision of confirmatory diagnoses
PANAMA	2024-02-29	CFT, IB, ELISA	10	0
PANAMA	2024-03-25	CFT, IB, ELISA	182	0

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOA Member?

No

## TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOA Members other than the own?

No

13. In exercising your activities, have you identified any regulatory research needs\* relevant for WOA?

No

## TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

No

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

No

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

b) International conferences:

c) National conferences:

d) Other (Provide website address or link to appropriate information):

## TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOA H Members?

Yes

a) Technical visit : 0

b) Seminars : 0

c) Hands-on training courses: 4

d) Internships (>1 month) 0

Type of technical training provided (a, b, c or d)	Country of origin of the expert(s) provided with training	No. participants from the corresponding country
C	ALGERIA	1
C	UKRAINE	3

## TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
DIN EN ISO/IEC 17025:2018	pdf	Akkreditierungsurkunde_2024.pdf

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
CFT, IB, PCR, ELISA, NGS	DAKKS

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

There are detailed written instructions about the issues of biosafety and biosecurity. All staff is trained and instructed once a year. At FLI a security screening of employees is installed and the access to the labs is regulated. Rules follow the German law of Biostoff-Verordnung, e.g. Access control to all labs by administrative regulations, Existence of a Biorisk Committee, regularly audits by external responsible authorities

## TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOA?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOA?

No

## TOR10: NETWORK WITH WOA REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOA Reference Laboratories designated for the same pathogen or disease?

Yes

24. Do you network (collaborate or share information) with other WOA Reference Laboratories designated for the same pathogen?

Yes

NETWORK/DISEASE	ROLE OF YOUR LABORATORY (PARTICIPANT, ORGANISER, ETC)	NO. PARTICIPANTS	PARTICIPATING WOA REF. LABS
Glanders	Participant at the Meeting of EU-Reference Laboratory	10	ANSES France

25. Did you organise or participate in inter-laboratory proficiency tests with WOA Reference Laboratories designated for the same pathogen during the past 2 years?

Yes

### Heinrich Neubauer - - GERMANY

Purpose of the proficiency test:	Role of your Reference Laboratory (organiser/ participant)	No. participating Laboratories	Participating WOAHL Ref. Labs/ organising WOAHL Ref Lab
PCR	Participant	16	EU-RL/ WOAHL-RL ANSES France
CFT	Participant	21	EU-RL/ WOAHL-RL ANSES France
ELISA	Organiser, Finalisation of report from the PT 2023	8	CVRL Dubai; ANSES-France

26. Did your laboratory collaborate with other WOAHL Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

Title of the project or contract	Scope	Name(s) of relevant WOAHL Reference Laboratories
Finalisation of PT	Report about inter-laboratory study to further validate serological diagnostic capacity of ID Screen Glanders Double Antigen Multispecies ELISA (GLANDA ELISA) in comparison with CFT	CVRL Duabi, ANSES France

## TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOAHL Reference Laboratories for the same pathogen during the past 2 years?

Yes

Purpose for inter-laboratory test comparisons <sup>1</sup>	Role of your reference laboratory (organizer/participant)	No. participating laboratories	Name of the test	WOAHL Member Countries
CFT	Participant	17	CFT	FRANCE,

## TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOAHL?

No

29. Additional comments regarding your report:

No